Recent Updates
Recently added Catalysts

EMD 72000+ ECX

Phase 1

Esophageal Cancer | Monoclonal antibody | Oncology |Merck KGaA|Trials Updated: Feb 19, 2014

Success Probability

Subscribe to view

Market & Valuation

Subscribe to view

Trial Design

UNCONTROLLEDBiomarker
Total Trials1
Total Enrollment26

FDA Designations

No designations recorded

EMD 72000+ ECX clinical trials

EMD 72000+ ECX · 1 trial · 2 indications

Phase 1 1
NCT00113581Safety Study of EMD 72000 in Combination With ECX (Epirubicin, Cisplatin and Capecitabine) in Oesophagogastric CancerEsophageal Cancer
COMPLETED26 Analytics
PHASE1COMPLETED
Safety Study of EMD 72000 in Combination With ECX (Epirubicin, Cisplatin and Capecitabine) in Oesophagogastric Cancer
Esophageal Cancer
NCT0011358126
Unlock trial analytics

Study Endpoints

Primary Endpoints

Safety and tolerability

Secondary Endpoints

Pharmacodynamic parameters
Pharmacokinetic parameters
Response rate
Unlock Study Endpoints

Study Design & Arms

AllocationNON_RANDOMIZED
MaskingNONE
ModelSINGLE_GROUP
PurposeTREATMENT

Interventions

NameTypeDescription
EMD 72000 (matuzumab) + ECXDRUG -
Unlock Study Design Details

Eligibility Criteria

Age Range18 Years to N/A
SexALL
Healthy VolunteersNo
Study Sites1

Inclusion Criteria: * Advanced, recurrent or metastatic gastric adenocarcinoma or adenocarcinoma of the lower third of the esophagus * EGFR positive tumor * KPS greater than 60 * Normal cardiac function * Adequate liver and bone marrow function * GFR greater than 60 ml/minute Exclusion Criteria: ...

Countries:United Kingdom
Unlock Eligibility Criteria

Competitive Landscape -Esophageal Cancer 156 trials

Top 20 of 40 competitors

CompanyTickerTrialsLead PhaseDrugs
AstraZeneca PLCAZN14PHASE3Durvalumab, AZD0901, Trastuzumab deruxtecan, Sonesitatug Vedotin, Rilvegostomig
Merck & Co., Inc.MRK12PHASE3Sacituzumab tirumotecan, Pembrolizumab, Ifinatamab Deruxtecan, Patritumab Deruxtecan, MK-4830
Jazz Pharmaceuticals Public Limited CompanyJAZZ5PHASE3Zanidatamab
BeOne Medicines Ltd. Sponsored ADRONC9PHASE3Tislelizumab, Zanidatamab, BG-68501, BGB-43395
Pfizer Inc.PFE8PHASE2Disitamab vedotin, Tucatinib, Trastuzumab, PF-08634404, PF-08046876
AbbVie, Inc.ABBV4PHASE2Telisotuzumab Adizutecan, Budigalimab, ABBV-400, ABBV-253
Eli Lilly and CompanyLLY4PHASE2Ramucirumab, LY4101174, LY4052031, LY4337713
Novartis AG Sponsored ADRNVS2PHASE2Spartalizumab, KFA115
ALX Oncology Holdings, Inc.ALXO2PHASE2Evorpacept, ALX2004
Bristol-Myers Squibb CompanyBMY4PHASE1Nivolumab, Nab-paclitaxel
Apollomics Inc. Class AAPLM1PHASE2APL-101
Exelixis, Inc.EXEL3PHASE1Cabozantinib, XB010
IDEAYA Biosciences, Inc.IDYA2PHASE1IDE892, IDE397, IDE034
Arcus Biosciences, Inc.RCUS1PHASE1AB598, Zimberelimab
NovaBridge Biosciences Sponsored ADRNBP2PHASE2Givastomig
Gilead Sciences, Inc.GILD1PHASE2Denikitug
Incyte CorporationINCY1PHASE2Retifanlimab
Sanofi SA Sponsored ADRSNY1PHASE2SAR445877
Nurix Therapeutics, Inc.NRIX1PHASE1NX-1607
Legend Biotech Corp. Sponsored ADRLEGN1PHASE1LB1908
Unlock Competitive Intelligence

Explore more on BiopharmaWatch

Merck KGaA (MKGAF)Pipeline, catalysts, financials, insiders and newsBiotech disease mapWho is developing what in each indication, and how crowded it isFDA calendarUpcoming PDUFA dates, AdComs and approval oddsPDUFA calendarEvery scheduled FDA decision date, month by monthHistorical FDA calendarPast decisions and how the stock moved on eachCatalyst SyncUpcoming readouts and decisions, screened by runway and phaseBiotech stock screenerFilter by clinical phase, cash runway and market capDrugs A to ZEvery drug page starting with ECompanies A to ZEvery biotech and pharma company we track